Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the Australian National Diabetes Audit from 2013 to 2019

To investigate temporal changes in glycaemic control and the use of antihyperglycaemic therapies in females and males with type 2 diabetes from 2013 to 2019.

[1]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[2]  P. Groeneveld,et al.  Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US , 2021, JAMA network open.

[3]  F. Giorgino,et al.  Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk , 2020, Cardiovascular Diabetology.

[4]  C. Wanner,et al.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Woodward,et al.  Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta‐Analysis , 2020, Journal of the American Heart Association.

[6]  A. Singh,et al.  Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. , 2020, Diabetes & metabolic syndrome.

[7]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[8]  J. Regensteiner,et al.  Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course , 2019, Diabetologia.

[9]  Soma Das,et al.  Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study , 2019, BMJ Open Diabetes Research & Care.

[10]  A. Farmer,et al.  Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017 , 2019, Diabetes, obesity & metabolism.

[11]  A. Reingold,et al.  Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela , 2019, BMJ Open.

[12]  J. Thumboo,et al.  Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017 , 2019, Journal of diabetes.

[13]  M. Gulati,et al.  Gender Differences in Patient‐Reported Outcomes Among Adults With Atherosclerotic Cardiovascular Disease , 2018, Journal of the American Heart Association.

[14]  M. Quiñones,et al.  Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review , 2018, Advances in Therapy.

[15]  W. Kernan,et al.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.

[16]  John P H Wilding,et al.  Patients’ Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography , 2018, Diabetes Therapy.

[17]  L. Smeeth,et al.  Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017 , 2018, BMJ Open.

[18]  E. Tai,et al.  Longitudinal trends in HbA1c patterns and association with outcomes: A systematic review , 2018, Diabetes/metabolism research and reviews.

[19]  G. Booth,et al.  Evolving Trends in the Epidemiology, Risk Factors, and Prevention of Type 2 Diabetes: A Review. , 2018, The Canadian journal of cardiology.

[20]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. , 2018, Diabetes research and clinical practice.

[21]  A. Fryer,et al.  Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit , 2018, Diabetes, obesity & metabolism.

[22]  G. Reach,et al.  Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. , 2017, Diabetes & metabolism.

[23]  J. Shaw,et al.  Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes , 2017, Diabetes Care.

[24]  A. Kautzky-Willer,et al.  Sex and gender differences in therapy of type 2 diabetes. , 2017, Diabetes research and clinical practice.

[25]  W. Polonsky,et al.  Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control , 2017, Diabetes Care.

[26]  F. Mauvais-Jarvis.  Gender differences in glucose homeostasis and diabetes , 2017, Physiology & Behavior.

[27]  T. Vos,et al.  Global, regional, and national incidence and prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017 .

[28]  S. Edelman,et al.  Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014 , 2017, Diabetes Therapy.

[29]  Till Bärnighausen,et al.  The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. , 2017, The lancet. Diabetes & endocrinology.

[30]  Huilin Tang,et al.  Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials , 2017, Diabetes, obesity & metabolism.

[31]  H. Yokoyama,et al.  Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40) , 2016, BMJ Open Diabetes Research and Care.

[32]  D. Mauricio,et al.  Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study , 2016, BMJ Open.

[33]  T. Gill,et al.  Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013 , 2016, Diabetes Care.

[34]  G. Pacini,et al.  Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus , 2016, Endocrine reviews.

[35]  K. Khunti,et al.  Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes , 2015, Cardiovascular Diabetology.

[36]  A. Kautzky-Willer,et al.  Gender‐based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient‐level pooled data of six randomized controlled trials , 2015, Diabetes, obesity & metabolism.

[37]  Marc Suhrcke,et al.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review , 2015, PharmacoEconomics.

[38]  M. Alvarsson,et al.  Sex differences in type 2 diabetes: focus on disease course and outcomes , 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

[39]  Tanjala S. Purnell,et al.  Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review , 2014, Diabetes Care.

[40]  P. de Pablos-Velasco,et al.  Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study , 2014, Clinical endocrinology.

[41]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[42]  Simone Rossi,et al.  Australian Medicines Handbook , 2012 .

[43]  A. Tiwari,et al.  Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. , 2011 .

[44]  V. Fonseca.  Defining and Characterizing the Progression of Type 2 Diabetes , 2009, Diabetes Care.

[45]  S. Colagiuri,et al.  Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus , 2009, The Medical journal of Australia.

[46]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[47]  Paul E. Johnson,et al.  Clinical Inertia and Outpatient Medical Errors , 2008 .

[48]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[49]  A. Melander,et al.  Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function , 1998, European Journal of Clinical Pharmacology.

[50]  Hypoglycemia in the Diabetes Control and Complications Trial , 1997, Diabetes.

[51]  Ž. Metelko,et al.  Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment , 1996, Diabetologia.

[52]  T. Carline,et al.  Gender Differences in Living with Diabetes Mellitus , 2013, Materia socio-medica.

[53]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[54]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[55]  Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. , 1997, Diabetes.